Back to top

The Zacks Analyst Blog Highlights: Medicines Co., Tekmira, GW Pharmaceuticals, Biogen and Alexion

Read MoreHide Full Article
For Immediate Release
 
Chicago, IL – April 16, 2015 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Medicines Co. (MDCO - Free Report) -Free Report), Tekmira -Free Report), GW Pharmaceuticals (GWPH - Free Report) -Free Report), Biogen (BIIB - Free Report) -Free Report) and Alexion (ALXN - Free Report) -Free Report).
                    
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:     
               

Biotech Stock Roundup
 
The Medicines Co. (MDCO - Free Report) -Free Report) was in the news for different reasons last week – while the company reported disappointing preliminary top-line results for the first quarter, later on the company received some good news with the FDA issuing positive briefing documents for Kengreal ahead of an advisory panel meeting. Other companies making it to the headlines over the last five trading days include Tekmira -Free Report) and GW Pharmaceuticals (GWPH - Free Report) -Free Report).

Recap of the Week’s Most Important Stories

1. The Medicines Co. has been in the news frequently this past week with the company providing preliminary top-line results. Moreover, the FDA released briefing documents ahead of an advisory panel meeting for Kengreal (Cangrelor). The company’s preliminary first quarter revenue expectations of $125 million - $130 million were disappointing (Read more: The Medicines Co. Posts Disappointing Preliminary Results) with Angiomax expected to record a significant decline in revenues from the year-ago period.

Meanwhile, an FDA advisory panel is meeting today to discuss the company’s new drug application for blood thinner Kengreal. Based on the positive tone of the briefing documents, the company may very well get a positive recommendation which could be followed by FDA approval by Jun 23. Kengreal gained EU approval in late March (Read more: The Medicines Co.'s Kengreal Briefing Documents Positive).

2. Tekmira received some encouraging news with the FDA informing the company that it has modified the partial clinical hold on the company's Investigational New Drug application (IND) for TKM-Ebola. As a result, repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day will be allowed. However, the partial clinical hold with regard to doses above 0.24 mg/kg/day in healthy volunteers will remain in place. Tekmira is now looking to resume the phase I study shortly (Read more: Tekmira Up on Ebola Candidate Update from the FDA).

3. Biogen (BIIB - Free Report) -Free Report) provided detailed phase II results on anti-LINGO-1 for acute optic neuritis. The company, which had provided top-line results earlier this year, reported a statistically significant improvement in recovery of optic nerve conduction latency as compared to placebo. The data will be presented at the upcoming annual meeting of the American Academy of Neurology (AAN).

4. GW Pharmaceuticals also had a positive update on the pipeline front with the company reporting the release of encouraging data by the American Academy of Neurology. The data, from an open-label study on the company’s medicinal liquid form of marijuana – Epidiolex – showed a reduction in the rate of seizures in people with epilepsy. Shares were up 13.1% on the news. Epidiolex is currently in a phase III study for Dravet syndrome with phase III studies for Lennox-Gastaut syndrome expected to commence in the second quarter of 2015.

5. Alexion’s (ALXN - Free Report) -Free Report) label for Soliris has been updated in the EU – the paroxysmal nocturnal haemoglobinuria (PNH) indication now includes patients without a history of transfusion. Meanwhile, the atypical hemolytic uremic syndrome (aHUS) section of the label has been updated to include new efficacy data stating that longer-term treatment with Soliris was linked to a higher proportion of patients achieving clinically significant benefits (Read more: Alexion Up as Soliris Gains EU Nod for Label Updates).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research            

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.


More from Zacks Press Releases

You May Like